Antiviral activity against Japanese encephalitis virus RP-9 infected in C57BL/6 mouse assessed as mouse survival rate at 1 ug, ip administered one day before and 1 day after viral infection measured after 25 days post infection relative to solvent treated control
Antiviral activity against Japanese encephalitis virus RP-9 infected in Stat-1-knockout immunodeficient C57BL/6 mouse assessed as mouse survival rate at 1 ug, ip administered one day before and 1 day after viral infection measured after 25 days post infection relative to solvent treated control
Antiviral activity against Japanese encephalitis virus RP-9 infected in Ig-mu chain-knockout immunodeficient C57BL/6 mouse assessed as mouse survival rate at 1 ug, ip administered one day before and 1 day after viral infection measured after 25 days post infection relative to solvent treated control
Antiviral activity against Japanese encephalitis virus RP-9 infected in C57BL/6 mouse assessed as mouse survival rate at 1 ug, ip administered one day before viral infection measured after 25 days post infection relative to solvent treated control
Antiviral activity against Japanese encephalitis virus RP-9 infected in C57BL/6 mouse assessed as mouse survival rate at 1 ug, ip administered simultaneously with viral infection measured after 25 days post infection relative to solvent treated control
Antiviral activity against Japanese encephalitis virus RP-9 infected in C57BL/6 mouse assessed as mouse survival rate at 1 ug, ip administered one day after viral infection measured after 25 days post infection relative to solvent treated control
Antibacterial activity against Sphingomonas capsulata ATCC 14666 infected in C57BL/6 mouse assessed as reduction in lung bacterial load at 50 ug/kg, ip administered 2 hrs post infection measured 24 hrs post infection
Antibacterial activity against luminescent Staphylococcus aureus Xen29 infected in BALB/c mouse deep thigh wound infection model assessed as reduction in bacterial load at 150 ug/kg, ip administered 3 hrs post infection by iVIS in-vivo imaging system
Antibacterial activity against luminescent Staphylococcus aureus Xen29 infected in BALB/c mouse deep thigh wound infection model assessed as reduction in bacterial load at 150 ug/kg, ip administered immediately after infection measured 48 hrs post infection by iVIS in-vivo imaging system
Antibacterial activity against luminescent Staphylococcus aureus Xen29 infected in BALB/c mouse deep thigh wound infection model assessed as reduction in bacterial load at 150 ug/kg, ip administered 6 hr post infection after infection measured 48 hrs post infection by iVIS in-vivo imaging system